(Y. Okuyama-Nishida, N. Akiyama, G. Sugimori, K. Nomura, K. Ogawa, K.J. Homma, K. Sekimizu, M. Tsujimoto, S. Natori. 2009. Prevention of death in bacterium-infected mice by a synthetic antimicrobial peptide, L5, through activation of host immunity. Antimicrobial Agents and Chemotherapy, 53. 6: 2510-2516.)
New Vaccination Strategy May Protect Against Both Lethal 1918 and H5N1 Influenza Viruses
A new study suggests that vaccination with 1918 H1N1 influenza virus-like particles not only protected mice and ferrets against the lethal 1918 influenza virus, but also displayed cross-reactive immunity against the potentially pandemic H5N1 influenza virus. The researchers from the National Center for Immunization and Respiratory Diseases, Collaborating Centers for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; and Novavax, Inc., Rockville, Maryland report their findings in the June 2009 issue of the Journal of Virology.
More than 220,000 hospitalizations and approximately 36,000 deaths are attributed to influenza A viruses each year. Since the first confirmed human cases of avian influenza in 1997, more than 400 additional human H5N1 infections have occurred of which an estimated 60% have been fatal. As new subtypes continue to emerge and the threat of a pandemic is at its highest in decades, researchers are pursuing vaccine strategies that can induce cross-reactive immunity against multiple strains of influenza viruses.
In prior research virus-like particle (VLP) vaccines have proven to be a promising new technology at preventing diseases in humans. VLPs resemble their live-virus counterparts and are readily processed by the immune system,
|Contact: Carrie Slijepcevic|
American Society for Microbiology